Levair I Transhaler

Levair I Transhaler Uses, Dosage, Side Effects, Food Interaction and all others data.

Levair I Transhaler Nebuliser Solution is a sterile, clear, colorless, preservative-free solution of the hydrochloride salt of Levair I Transhaler, the (R)-enantiomer of the drug substance racemic salbutamol. Levair I Transhaler Hydrochloride is a relatively selective &beta 2 adrenergic receptor agonist.

Activation of &beta 2 adrenergic receptors on airway smooth muscle leads to the activation of adenylcyclase and to an increase in the intracellular concentration of cyclic AMP. This increase in cAMP leads to the activation of protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in relaxation. Levair I Transhaler relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Levair I Transhaler acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor.

It acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.

Levair I Transhaler
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Levair I Transhaler
Generic	Levosalbutamol
Levosalbutamol Other Names	(R)-salbutamol, Levalbuterol, Levosalbutamol, R-salbutamol
Type
Formula	C₁₃H₂₁NO₃
Weight	Average: 239.3107 Monoisotopic: 239.152143543
Protein binding	plasma protein binding is relatively low.
Groups	Approved, Investigational
Therapeutic Class	Short-acting selective β2-adrenoceptor stimulants
Manufacturer	Lupin
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Levair I Transhaler tablet is used for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Levair I Transhaler Nebuliser Solution or Inhaler is used for the treatment or prevention of bronchospasm in adults, adolescents, and children with reversible obstructive airway disease.

Levair I Transhaler is also used to associated treatment for these conditions: Bronchospasm

How Levair I Transhaler works

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Dosage

Levair I Transhaler dosage

Levair I Transhaler Tablet-

Adults and children above 12 years: 1-2 mg three times daily.
Children (6 -11 years): 1 mg three times daily.

Syrup-

Adults and children above 12 years: 5-10 ml three times daily.
Children (6 -11 years): 5 ml three times daily.

Levair I Transhaler Nebuliser Solution-

This Nebuliser Solutionis supplied in unit-dose ampoules and requires no dilution before administration by nebulization.

Children (6 months-11 years): The recommended dosage is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day.
Adults and Adolescents above 12 years old: The recommended starting dosage is 0.63 mg administered three to four times a day, every 6 to 8 hours, by nebulization.
Patients 12 years of age and older with more severe asthma or patients who do not respond adequately: 0.63 mg of Levair I Transhaler Nebuliser Solution may benefit from a dosage of 1.25 mg three times a day.

Levair I Transhaler Inhaler-

You should take your Levair I Transhaler Inhaler as needed for an asthma attack at any time of day, with or without food, by taking 1-2 puffs up to 4 times daily and no more than 8 puffs in 24 hours. If you are using your Levair I Transhaler Inhaler more than 3-4 times a week this may indicate that your asthma is not well controlled and you may need to review your medication. You can also use your Levair I Transhaler Inhaler to prevent allergy or exercise induced asthma by taking 2 puffs 15 minutes before exercise or exposure to a known allergen.

Side Effects

Potentially serious side effects like hypokalamia may result from ß-2 agonist therapy. This effect may be potentiated by hypoxia. The other likely side effects are gastrointestinal disturbances such as nausea, vomiting, burning substernal or epigastric pain and diarrhoea. In some cases nervousness, headache, dizziness, fatigue and sleeplessness may occur.

Precaution

Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations. Oral Levair I Transhaler should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias or hypertension. Levair I Transhaler can be used with caution after myocardial infarction.

Levair I Transhaler Hydrochloride, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, hypertension, and cardiac arrhythmias; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Levair I Transhaler Nebuliser Solution or Inhaler must not be injected.

Interaction

Other short-acting sympathomimetic bronchodilators or epinephrine should be used with caution with Levair I Transhaler. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

Food Interaction

No interactions found.

Elimination Route

Inhalation delivers the medication directly into the airways and lungs, thereby minimizing side effects because of reduced systemic absorption of the inhaled medications.

Half Life

3.3 - 4 hours

Elimination Route

excreted into the urine.

Pregnancy & Breastfeeding use

Use in pregnancy: Use of oral Levair I Transhaler in pregnant women should be considered only if the expected benefit to the mother is greater than any possible risk to the foetus or the infant.

Use in lactation: It is not known whether Levair I Transhaler is excreted in human milk. Caution should be exercised when oral Levair I Transhaler is administered to a nursing woman.

Pregnancy: There are no adequate and well-controlled studies of Levair I Transhaler Nebuliser Solution in pregnant women. Levair I Transhaler Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: It is not known whether Levair I Transhaler is excreted in human milk. Caution should be exercised when Levair I Transhaler Nebuliser Solution is administered to a nursing woman.

Contraindication

Levair I Transhaler Nebuliser Solution is contraindicated in patients with a history of hypersensitivity to Levair I Transhaler Hydrochloride or racemic salbutamol.

Acute Overdose

The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under side effects e.g., tachycardia, nervousness, headache, tremor, nausea, dizziness, fatigue and sleeplessness. Hypokalaemia also may occur. Treatment consists of discontinuation of oral Levair I Transhaler together with appropriate symptomatic therapy. In the event of serious poisoning, the stomach should be emptied and, if necessary, a beta-blocker administered with caution in patients with a history of bronchospasm.